GUD Knight Therapeutics Inc.
10.36CAD+0.39%Mkt Cap: 741.14M $P/E: 69.071d ago
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refr…
Industry Peers
Drug Manufacturers - Specialty & Generic$64.30BUSDP/E 25.0
$56.90BUSD
$46.26BUSDP/E 66.1
$38.79BUSDP/E 18.0
$29.51BUSDP/E 11.7
$28.27BUSDP/E 12.1
$23.01BUSDP/E 19.2
$20.24BUSD
$14.14BUSDP/E 110.6
$14.66BUSDP/E 21.1
$12.60BUSDP/E 22.8
$11.25BUSD
$10.26BUSDP/E 28.0
$8.59BUSDP/E 19.2
$7.17BUSDP/E 112.5
$7.09BUSDP/E 41.5
$6.92BUSD
$6.54BUSDP/E 24.3
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.$5.17BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Knight Therapeutics Q2 Earnings Call Highlights Knight Therapeutics (TSE:GUD) reported record results for the first six months of 2026 and raised its full-year outlook, citing growth in its promoted products, contributions from recent launches and favorable foreign-exchange effects. For the first half of 2026, the company reported revenue of CAD | ||
Knight Therapeutics Inc (KHTRF) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ... Knight Therapeutics Inc (KHTRF) posts a 34% revenue surge to $144 million in Q2 2026, driven by robust product launches and a raised full-year outlook. | ||